Beximco Pharmaceuticals Limited

DSE:BXPHARMA Voorraadrapport

Marktkapitalisatie: ৳33.1b

Beximco Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Beximco Pharmaceuticals is forecast to grow earnings and revenue by 15.6% and 12.8% per annum respectively. EPS is expected to grow by 18.3% per annum. Return on equity is forecast to be 14.8% in 3 years.

Belangrijke informatie

15.6%

Groei van de winst

18.3%

Groei van de winst per aandeel

Pharmaceuticals winstgroei17.1%
Inkomstengroei12.8%
Toekomstig rendement op eigen vermogen14.8%
Dekking van analisten

Low

Laatst bijgewerkt09 May 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DSE:BXPHARMA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (BDT Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/202764,9498,6887,3529,2163
6/30/202657,1717,4646,8688,5453
6/30/202550,4236,2445,7197,1513
6/30/202444,5065,2514,8946,1463
3/31/202443,0855,3305,9628,373N/A
12/31/202341,6524,9165,6968,176N/A
9/30/202340,6394,7205,4868,109N/A
6/30/202339,2674,6143,4426,085N/A
3/31/202337,9744,4772,6505,562N/A
12/31/202237,3794,6291,3233,922N/A
9/30/202235,9875,1051,1613,910N/A
6/30/202234,6695,1232,2755,214N/A
3/31/202233,6605,7383,1435,950N/A
12/31/202132,0626,0974,1537,502N/A
9/30/202131,0375,5193,9836,796N/A
6/30/202129,4945,1283,4656,023N/A
3/31/202128,2694,5783,6675,592N/A
12/31/202027,5174,0172,1984,025N/A
9/30/202026,2353,7242,3544,895N/A
6/30/202025,6123,5153,2675,542N/A
3/31/202025,0563,405-1874,319N/A
12/31/201924,2023,2518345,814N/A
9/30/201923,7353,143-1144,397N/A
6/30/201922,8173,033-1,5852,960N/A
3/31/201921,7242,852-3002,893N/A
12/31/201820,1882,708-2,3931,397N/A
9/30/201818,8232,647-3,1061,611N/A
6/30/201817,7172,537-3,2391,819N/A
3/31/201816,9242,513-2,5472,416N/A
12/31/201716,5172,431N/A2,873N/A
9/30/201716,0222,356N/A2,643N/A
6/30/201715,5092,227N/A2,634N/A
3/31/201714,6872,224N/A2,042N/A
12/31/201614,2712,133N/A1,883N/A
9/30/201613,7362,060N/A1,932N/A
6/30/201613,3561,965N/A2,113N/A
12/31/201512,9661,954N/A1,835N/A
9/30/201512,5731,804N/A2,095N/A
6/30/201512,1341,813N/A1,937N/A
3/31/201511,6281,605N/A2,510N/A
12/31/201411,2071,528N/A2,216N/A
9/30/201411,1391,476N/A2,459N/A
6/30/201410,8471,471N/A2,146N/A
3/31/201410,8041,452N/A2,196N/A
12/31/201310,4911,405N/A2,130N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: BXPHARMA's forecast earnings growth (15.6% per year) is above the savings rate (3.7%).

Winst versus markt: BXPHARMA's earnings (15.6% per year) are forecast to grow slower than the BD market (17.3% per year).

Hoge groeiwinsten: BXPHARMA's earnings are forecast to grow, but not significantly.

Omzet versus markt: BXPHARMA's revenue (12.8% per year) is forecast to grow faster than the BD market (9.3% per year).

Hoge groei-inkomsten: BXPHARMA's revenue (12.8% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: BXPHARMA's Return on Equity is forecast to be low in 3 years time (14.8%).


Ontdek groeibedrijven